Vertex Pharmaceuticals Thrives on Higher Sales and Guidance

Vertex Pharmaceuticals Thrives on Higher Sales and Guidance

来源:FXEmpire发布于 2026-11-04

VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.

相关标的:VRTX

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。